Genelux Corporation Common Stock (GNLX) - Total Assets
Based on the latest financial reports, Genelux Corporation Common Stock (GNLX) holds total assets worth $24.99 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See GNLX book value for net asset value and shareholders' equity analysis.
Genelux Corporation Common Stock - Total Assets Trend (2019–2024)
This chart illustrates how Genelux Corporation Common Stock's total assets have evolved over time, based on quarterly financial data.
Genelux Corporation Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Genelux Corporation Common Stock's total assets of $24.99 Million consist of 90.9% current assets and 9.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 24.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Genelux Corporation Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Genelux Corporation Common Stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genelux Corporation Common Stock's current assets represent 90.9% of total assets in 2024, an increase from 16.8% in 2019.
- Cash Position: Cash and equivalents constituted 24.7% of total assets in 2024, up from 13.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Genelux Corporation Common Stock Competitors by Total Assets
Key competitors of Genelux Corporation Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Genelux Corporation Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.20 | 6.47 | 0.79 |
| Quick Ratio | 4.20 | 6.47 | 0.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $16.43 Million | $30.41 Million | $-3.02 Million |
Genelux Corporation Common Stock - Advanced Valuation Insights
This section examines the relationship between Genelux Corporation Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.69 |
| Latest Market Cap to Assets Ratio | 3.39 |
| Asset Growth Rate (YoY) | 24.5% |
| Total Assets | $34.72 Million |
| Market Capitalization | $117.61 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Genelux Corporation Common Stock's assets at a significant premium (3.39x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Genelux Corporation Common Stock's assets grew by 24.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Genelux Corporation Common Stock (2019–2024)
The table below shows the annual total assets of Genelux Corporation Common Stock from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $34.72 Million | +24.46% |
| 2023-12-31 | $27.89 Million | +404.30% |
| 2022-12-31 | $5.53 Million | -31.93% |
| 2021-12-31 | $8.13 Million | -41.99% |
| 2020-12-31 | $14.01 Million | +326.94% |
| 2019-12-31 | $3.28 Million | -- |
About Genelux Corporation Common Stock
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or s… Read more